175 related articles for article (PubMed ID: 30289729)
1. Mutation Profiles in Glioblastoma 3D Oncospheres Modulate Drug Efficacy.
Wilson KM; Mathews-Griner LA; Williamson T; Guha R; Chen L; Shinn P; McKnight C; Michael S; Klumpp-Thomas C; Binder ZA; Ferrer M; Gallia GL; Thomas CJ; Riggins GJ
SLAS Technol; 2019 Feb; 24(1):28-40. PubMed ID: 30289729
[TBL] [Abstract][Full Text] [Related]
2. Drug Screening of Human GBM Spheroids in Brain Cancer Chip.
Akay M; Hite J; Avci NG; Fan Y; Akay Y; Lu G; Zhu JJ
Sci Rep; 2018 Oct; 8(1):15423. PubMed ID: 30337660
[TBL] [Abstract][Full Text] [Related]
3. High-Throughput 3D Tumor Spheroid Screening Method for Cancer Drug Discovery Using Celigo Image Cytometry.
Kessel S; Cribbes S; Déry O; Kuksin D; Sincoff E; Qiu J; Chan LL
SLAS Technol; 2017 Aug; 22(4):454-465. PubMed ID: 27272155
[TBL] [Abstract][Full Text] [Related]
4. A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses.
Gomez-Roman N; Stevenson K; Gilmour L; Hamilton G; Chalmers AJ
Neuro Oncol; 2017 Feb; 19(2):229-241. PubMed ID: 27576873
[TBL] [Abstract][Full Text] [Related]
5. An orthotopic glioblastoma animal model suitable for high-throughput screenings.
Pudelko L; Edwards S; Balan M; Nyqvist D; Al-Saadi J; Dittmer J; Almlöf I; Helleday T; Bräutigam L
Neuro Oncol; 2018 Oct; 20(11):1475-1484. PubMed ID: 29750281
[TBL] [Abstract][Full Text] [Related]
6. Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening.
Griner LM; Gampa K; Do T; Nguyen H; Farley D; Hogan CJ; Auld DS; Silver SJ
J Vis Exp; 2018 Sep; (139):. PubMed ID: 30247463
[TBL] [Abstract][Full Text] [Related]
7. Real-Time Apoptosis and Viability High-Throughput Screening of 3D Multicellular Tumor Spheroids Using the Celigo Image Cytometer.
Kessel S; Cribbes S; Bonasu S; Qiu J; Chan LL
SLAS Discov; 2018 Feb; 23(2):202-210. PubMed ID: 28915356
[TBL] [Abstract][Full Text] [Related]
8. High-dose drug heat map analysis for drug safety and efficacy in multi-spheroid brain normal cells and GBM patient-derived cells.
Lee SY; Teng Y; Son M; Ku B; Moon HS; Tergaonkar V; Chow PK; Lee DW; Nam DH
PLoS One; 2021; 16(12):e0251998. PubMed ID: 34855773
[TBL] [Abstract][Full Text] [Related]
9. Hydrogel matrix presence and composition influence drug responses of encapsulated glioblastoma spheroids.
Hill L; Bruns J; Zustiak SP
Acta Biomater; 2021 Sep; 132():437-447. PubMed ID: 34010694
[TBL] [Abstract][Full Text] [Related]
10. Cancer cell spheroids for screening of chemotherapeutics and drug-delivery systems.
Patel NR; Aryasomayajula B; Abouzeid AH; Torchilin VP
Ther Deliv; 2015; 6(4):509-20. PubMed ID: 25996047
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.
Gravina GL; Mancini A; Mattei C; Vitale F; Marampon F; Colapietro A; Rossi G; Ventura L; Vetuschi A; Di Cesare E; Fox JA; Festuccia C
Oncotarget; 2017 May; 8(18):29865-29886. PubMed ID: 28415741
[TBL] [Abstract][Full Text] [Related]
12. Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma.
Skaga E; Kulesskiy E; Fayzullin A; Sandberg CJ; Potdar S; Kyttälä A; Langmoen IA; Laakso A; Gaál-Paavola E; Perola M; Wennerberg K; Vik-Mo EO
BMC Cancer; 2019 Jun; 19(1):628. PubMed ID: 31238897
[TBL] [Abstract][Full Text] [Related]
13. Hydrogel-Based Spheroid Models of Glioblastoma for Drug Screening Applications.
Bruns J; Zustiak SP
Mo Med; 2021; 118(4):346-351. PubMed ID: 34373670
[TBL] [Abstract][Full Text] [Related]
14. High-content assays for characterizing the viability and morphology of 3D cancer spheroid cultures.
Sirenko O; Mitlo T; Hesley J; Luke S; Owens W; Cromwell EF
Assay Drug Dev Technol; 2015 Sep; 13(7):402-14. PubMed ID: 26317884
[TBL] [Abstract][Full Text] [Related]
15. Bionic 3D spheroids biosensor chips for high-throughput and dynamic drug screening.
Wu Q; Wei X; Pan Y; Zou Y; Hu N; Wang P
Biomed Microdevices; 2018 Sep; 20(4):82. PubMed ID: 30220069
[TBL] [Abstract][Full Text] [Related]
16. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma.
Singh MM; Johnson B; Venkatarayan A; Flores ER; Zhang J; Su X; Barton M; Lang F; Chandra J
Neuro Oncol; 2015 Nov; 17(11):1463-73. PubMed ID: 25795306
[TBL] [Abstract][Full Text] [Related]
17. Single and Combination Drug Screening with Aqueous Biphasic Tumor Spheroids.
Shahi Thakuri P; Tavana H
SLAS Discov; 2017 Jun; 22(5):507-515. PubMed ID: 28324660
[TBL] [Abstract][Full Text] [Related]
18. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Hepatic Functions of Genetically Modified Mouse Hepatoma Cells by Spheroid Culture for Drug Toxicity Screening.
Sarkar J; Kumari J; Tonello JM; Kamihira M; Kumar A
Biotechnol J; 2017 Oct; 12(10):. PubMed ID: 28834334
[TBL] [Abstract][Full Text] [Related]
20. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
